Drugs / Olomorasib
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07439250 | Mar → Apr 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT07124013 | Sep 2025 → Jan 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT07137689 | Aug 2025 → Apr 2026 | impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT07044271 | Jul → Nov 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06719128 | Dec 2024 → Aug 2025 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06235983 | Feb 2024 → Jul 2025 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06111521 | Oct 2023 → Apr 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05901311 | Jun → Aug 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05860933 | May → Aug 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05824858 | Apr → Jun 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07227025 | Mar 2026 → Nov 2028 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04956640 | Jul 2021 → Apr 2027 expected | biliary tract neoplasm, colorectal neoplasm, endometrium neoplasm, non-small cell lung carcinoma +2 | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07639242 | Jun 2026 → Jun 2030 expected | non-small cell lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06890598 | Mar 2025 → May 2029 expected | non-small cell lung carcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06119581 | Dec 2023 → Nov 2027 expected | metastatic neoplasm, non-small cell lung carcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olomorasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07439250 ↗ |
| Known as | LY3537982 | “A Study of Olomorasib (LY3537982) in Healthy Participants” NCT07439250 ↗ |
| Modality | Small molecule | — CHEMBL6068410 ↗ |
| Route | Oral | “Oral” NCT04956640 ↗ |